BIO vs PX · rev $2.58B vs P/E 67, rev $296.4M
BIO (BIO) versus P10 Inc (PX) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
P10 Inc (PX) is a asset management company listed on US.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported PX revenue for 2024-12-31 was $296.4M. Net income was $19.7M. Revenue was up 22.6% from 2023-12-31 to 2024-12-31. PX currently screens at market cap $1.21B and trailing P/E 67.2.
BIO currently screens at market cap $0. PX currently screens at market cap $1.21B and trailing P/E 67.2.
Not investment advice. Open the BIO and PX stock pages for the full models.
Not investment advice.